SIMULTANEOUS METHOD VALIDATION FOR THE ESTIMATION OF NIVOLUMAB AND CABOZANTINIB IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC METHOD
Fuente:
Zenodo
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Recurso digital |
| Lingua: | inglese |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901625728139264 |
|---|---|
| author | Dr. Sreenivasa Charan Archakam Dr. Keerthisikha Palur Bukke Nagalakshmi* Dr. Ranganayakulu Diviti |
| author_facet | Dr. Sreenivasa Charan Archakam Dr. Keerthisikha Palur Bukke Nagalakshmi* Dr. Ranganayakulu Diviti |
| contents | <p class="MsoNormal"><strong><span>Aim:</span></strong><span> </span><span>The present study aimed to progress a modest, novel, and specific method for the simultaneous evaluation of Nivolumab and Cabozantinib in bulk and tablet dosage form by Reverse-phase high-performance liquid chromatography (RP-HPLC). <strong>Material and Methods:</strong></span><span> </span><span>Nivolumab and Cabozantinib pure drugs (API), Combination Nivolumab and Cabozantinib Synthetic Formulation, Distilled water, Acetonitrile, Phosphate buffer, Methanol, Potassium dihydrogen ortho phosphate buffer, Ortho-phosphoric acid. All the above chemicals and solvents are from Rankem.</span><span> </span><span>Based on the solubility of the drugs, diluent was selected, Acetonitrile and H2O in the ratio of 50:50 v/v. <strong>Results:</strong> The method exhibited excellent precision with %RSD values of 0.7 for Nivolumab and 0.9 for Cabozantinib. Recovery studies revealed the method`s accuracy with recovery rates of 100.16% for Nivolumab and 99.63% for Cabozantinib. Limits of detection(LOD) and quantification(LOQ) were determined as 0.20 µg/mL, 0.03 µg/mL for Nivolumab and 0.61µg/mL,0.08 µg/mL for Cabozantinib. The regression equations obtained for Nivolumab and Cabozantinib were y =39306x + 12173 and y =34894x +1139.7 respectively. <strong>Conclusion:</strong></span><span> </span><span>The benefit is in the ease of sample preparation and the cost-effective use of fewer chemicals and the precision and reproducibility of the experimental data are good, according to statistical analysis.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19761594 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | SIMULTANEOUS METHOD VALIDATION FOR THE ESTIMATION OF NIVOLUMAB AND CABOZANTINIB IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC METHOD Dr. Sreenivasa Charan Archakam Dr. Keerthisikha Palur Bukke Nagalakshmi* Dr. Ranganayakulu Diviti Lamivudine Dolutegravir RP-HPLC Tablet dosage form Validation Quality control LOD LOQ Recovery %RSD <p class="MsoNormal"><strong><span>Aim:</span></strong><span> </span><span>The present study aimed to progress a modest, novel, and specific method for the simultaneous evaluation of Nivolumab and Cabozantinib in bulk and tablet dosage form by Reverse-phase high-performance liquid chromatography (RP-HPLC). <strong>Material and Methods:</strong></span><span> </span><span>Nivolumab and Cabozantinib pure drugs (API), Combination Nivolumab and Cabozantinib Synthetic Formulation, Distilled water, Acetonitrile, Phosphate buffer, Methanol, Potassium dihydrogen ortho phosphate buffer, Ortho-phosphoric acid. All the above chemicals and solvents are from Rankem.</span><span> </span><span>Based on the solubility of the drugs, diluent was selected, Acetonitrile and H2O in the ratio of 50:50 v/v. <strong>Results:</strong> The method exhibited excellent precision with %RSD values of 0.7 for Nivolumab and 0.9 for Cabozantinib. Recovery studies revealed the method`s accuracy with recovery rates of 100.16% for Nivolumab and 99.63% for Cabozantinib. Limits of detection(LOD) and quantification(LOQ) were determined as 0.20 µg/mL, 0.03 µg/mL for Nivolumab and 0.61µg/mL,0.08 µg/mL for Cabozantinib. The regression equations obtained for Nivolumab and Cabozantinib were y =39306x + 12173 and y =34894x +1139.7 respectively. <strong>Conclusion:</strong></span><span> </span><span>The benefit is in the ease of sample preparation and the cost-effective use of fewer chemicals and the precision and reproducibility of the experimental data are good, according to statistical analysis.</span></p> |
| title | SIMULTANEOUS METHOD VALIDATION FOR THE ESTIMATION OF NIVOLUMAB AND CABOZANTINIB IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC METHOD |
| topic | Lamivudine Dolutegravir RP-HPLC Tablet dosage form Validation Quality control LOD LOQ Recovery %RSD |
| url | https://doi.org/10.5281/zenodo.19761594 |